CIA
BPMC

CSat Investment Advisory’s Blueprint Medicines BPMC Stock Holding History

CSat Investment Advisory’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-221
Closed -$20K – 583
2020
Q3 		$20K Buy
221
+27
+14% +$2.08K ﹤0.01% 855
2020
Q2 		$15K Buy
+194
New +$13.1K ﹤0.01% 914

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CSat Investment Advisory's BPMC Position: Q4 2020 in Review

CSat Investment Advisory sold out of Blueprint Medicines (BPMC) in Q4 2020, closing a stake of 221 shares — an estimated $20K sold.

CSat Investment Advisory first reported a position in BPMC in Q2 2020 and held it in 2 quarters. The position peaked at $20K in Q3 2020. 279 funds tracked by Wall St. Rank hold BPMC as of Q4 2020.

  • CSat Investment Advisory reported no remaining Blueprint Medicines position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 221 Blueprint Medicines shares in Q4 2020, an estimated $20K.
  • CSat Investment Advisory first reported a position in Blueprint Medicines in Q2 2020 and held it in 2 quarters.
  • CSat Investment Advisory's Blueprint Medicines position peaked at $20K in Q3 2020.
  • 279 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.